Comprehensive gene expression analysis detects global reduction of proteasome subunits in schizophrenia

OBJECTIVE A main challenge in the study of schizophrenia is its high heterogeneity. While it is generally accepted that there exist several biological mechanisms that may define distinct schizophrenia subtypes, they haven’t been identified yet. We applied comprehensive gene expression analysis, searching for molecular signals that differentiate patients with schizophrenia from healthy controls, and examined whether the identified signal characterizes a particular subgroup of the patients. METHODS We performed transcriptome sequencing of 14 superior temporal gyrus (STG) samples of relatively young (mean age: 44) subjects with schizophrenia and 15 matched controls from the Stanley Medical Research Institute. Analyses of differential expression and pathway enrichment were applied and the results were compared with those obtained from an independent cohort of elderly (mean age: 74) patients. Replicability was then tested on six additional independent datasets of various brain regions. RESULTS The two STG cohorts of relatively young and elderly subjects showed high replicability. Pathway enrichment analysis of the down-regulated genes pointed to proteasome-related pathways. Meta-analysis of differential expression identified down-regulation of 12 of 39 proteasome subunits in schizophrenia. Down-regulation of multiple proteasome subunits was replicated in six additional datasets (overall 8 cohorts, with 267 schizophrenia and 266 control samples, from 5 brain regions, were studied). This signal was concentrated in a subgroup of the patients. CONCLUSIONS We detect global down-regulation of proteasome subunits in a subgroup of the patients with schizophrenia. The proteasome is a major intracellular protein degradation system, where ubiquitinated proteins (proteins bound by the small protein called ubiquitin) are targeted for degradation. We hypothesize that the down-regulation we detect leads to proteasome dysfunction that causes accumulation of ubiquitinated proteins. Such accumulation has recently been identified, also in a subgroup of the studied patients with schizophrenia. Thus, down-regulation of proteasome subunits might define a biological subtype of schizophrenia.

[1]  Stephen J Glatt,et al.  Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[2]  Christos Pantelis,et al.  Age of onset of schizophrenia: perspectives from structural neuroimaging studies. , 2011, Schizophrenia bulletin.

[3]  C. Ross,et al.  Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia. , 2019, The American journal of psychiatry.

[4]  K. Davis,et al.  Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. , 2005, International review of neurobiology.

[5]  C. Tamminga,et al.  F168. Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia , 2019, Biological Psychiatry.

[6]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[7]  E. Kemether,et al.  Thalamic transcriptome screening in three psychiatric states , 2009, Journal of Human Genetics.

[8]  V. Haroutunian,et al.  Dysfunction of the Ubiquitin Proteasome and Ubiquitin-Like Systems in Schizophrenia , 2013, Neuropsychopharmacology.

[9]  V. Haroutunian,et al.  Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.

[10]  V. Haroutunian,et al.  Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia , 2016, Neuropsychopharmacology.

[11]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[12]  S. Faraone,et al.  Genes, environment and schizophrenia. , 2001, The British journal of psychiatry. Supplement.

[13]  M. Tsuang,et al.  Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[14]  R. Granger,et al.  DLPFC Transcriptome Defines Two Molecular Subtypes of Schizophrenia , 2017, bioRxiv.

[15]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[16]  Ben-Ari FuchsShani,et al.  GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data , 2016 .

[17]  Terry M. Therneau,et al.  Faster cyclic loess: normalizing RNA arrays via linear models , 2004, Bioinform..

[18]  J. T. Webster,et al.  The Use of an F-Statistic in Stepwise Regression Procedures , 1972 .

[19]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Elijah F. W. Bowen,et al.  DLPFC transcriptome defines two molecular subtypes of schizophrenia , 2019, Translational Psychiatry.

[21]  W. Markesbery,et al.  Decreased levels of proteasome activity and proteasome expression in aging spinal cord , 2000, Neuroscience.

[22]  Aiqing He,et al.  Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder , 2014, Molecular Psychiatry.

[23]  Andrew L. Lemire,et al.  Deficient Hippocampal Neuron Expression of Proteasome, Ubiquitin, and Mitochondrial Genes in Multiple Schizophrenia Cohorts , 2005, Biological Psychiatry.

[24]  G. Godefroy,et al.  Voronoi tessellation to study the numerical density and the spatial distribution of neurones , 2000, Journal of Chemical Neuroanatomy.

[25]  R. Yolken,et al.  The Stanley Foundation brain collection and Neuropathology Consortium , 2000, Schizophrenia Research.

[26]  A. Rademaker,et al.  A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas , 2016, Journal of Neuro-Oncology.

[27]  Dan Tsafrir,et al.  Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices , 2005, Bioinform..

[28]  Kevin P. White,et al.  The transcription factor POU3F2 regulates a gene coexpression network in brain tissue from patients with psychiatric disorders , 2018, Science Translational Medicine.

[29]  J. Meador-Woodruff,et al.  Intracellular compartment-specific proteasome dysfunction in postmortem cortex in schizophrenia subjects , 2019, Molecular Psychiatry.

[30]  E. Morrow,et al.  Distribution of disease-associated copy number variants across distinct disorders of cognitive development. , 2013, Journal of the American Academy of Child and Adolescent Psychiatry.

[31]  M. Barnes,et al.  Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function , 2009, Molecular Psychiatry.

[32]  H. Fine,et al.  A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas , 2015, Journal of Neuro-Oncology.

[33]  C. Pantelis,et al.  Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia , 2019, Scientific Reports.

[34]  Benjamin A. Logsdon,et al.  Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia , 2016, Nature Neuroscience.

[35]  Stanley J. Watson,et al.  Post-mortem molecular profiling of three psychiatric disorders , 2016, Genome Medicine.

[36]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[37]  C. Davies,et al.  Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia , 2011, Journal of neuroscience research.

[38]  H. Friedman,et al.  Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Hakonarson,et al.  Common and Rare Genetic Risk Factors Converge in Protein Interaction Networks Underlying Schizophrenia , 2018, Front. Genet..

[40]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .